Kristin Baier, Calibrate's vice president of clinical development, acknowledged in an interview with Fortune that there was no research indicating these medications could be temporary at the company's conception
These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]
Biomaterials 110:1123
The weight-loss effects of Semaglutide, a long-acting GLP-1RA, are well-established,9 and this was confirmed in our elderly cohort
It's a complex, self-regulating circuit
Complementary Lifestyle Practices Beyond supplementation, various lifestyle practices support optimal glutathione function and overall antioxidant status